A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- <i>N,N</i> -dimethyltryptamine) in patients with treatment-resistant depression

Results confirmed the safety profile of BPL-003 in a TRD population. A rapid and sustained reduction in MADRS score was observed over 12 weeks, suggesting BPL-003 could be beneficial in TRD, warranting investigation in larger controlled trials.